C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
Holders of 5% or more of CCCC
Holders whose latest Schedule 13D or 13G filing reports 5% or more of C4 Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 13G/A | 9.99%10.4M shares | – | Feb 12, 20261 filing | Feb 12, 2026 | SEC |
| Point72 Asset Management, L.P. | 13G | 9.90%22.6M shares | New | Oct 20, 20251 filing | Oct 20, 2025 | SEC |
| Ra Capital Management, L.P. | 13G | 9.90%9.44M shares | +9.90 ppfrom 0.00% | May 15, 20252 filings | Oct 24, 2025 | SEC |
| Morgan Stanley | 13G/A | 9.30%8.97M shares | +2.60 ppfrom 6.70% | Feb 3, 20253 filings | Feb 11, 2026 | SEC |
| Lynx1 Capital Management LP | 13G/A | 7.30%7.10M shares | – | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| Wasatch Advisors Inc | 13G/A | 6.80%4.85M shares | −3.70 ppfrom 10.50% | May 7, 20252 filings | Nov 13, 2025 | SEC |
| Bain Capital Life Sciences Fund II, L.P. | 13G | 6.25%6.06M shares | New | Oct 24, 20251 filing | Oct 24, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
15 Schedule 13D and 13G filings on C4 Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 20266:18 PM ET | OrbiMed Advisors LLCand 1 other | 13G/A | 1.00%883.5K shares | −4.00 ppfrom 5.00%Below 5% | Dec 31, 2025 | SEC |
| Feb 17, 20261:45 PM ET | Lynx1 Capital Management LPand 1 other | 13G/A | 7.30%7.10M shares | – | Dec 31, 2025 | SEC |
| Feb 12, 20265:02 PM ET | Soleus Capital Master Fund, L.P.and 8 others | 13G/A | 9.99%10.4M shares | – | Dec 31, 2025 | SEC |
| Feb 11, 202612:58 PM ET | Morgan Stanleyand 1 other | 13G/A | 9.30%8.97M shares | +2.60 ppfrom 6.70% | Dec 31, 2025 | SEC |
| Nov 14, 20256:08 PM ET | OrbiMed Advisors LLCand 1 other | 13G/A | 5.00%3.57M shares | −1.60 ppfrom 6.60% | Sep 30, 2025 | SEC |
| Nov 13, 20255:33 PM ET | Wasatch Advisors Inc | 13G/A | 6.80%4.85M shares | −3.70 ppfrom 10.50% | Sep 30, 2025 | SEC |
| Oct 24, 20254:30 PM ET | Bain Capital Life Sciences Fund II, L.P.and 2 others | 13G | 6.25%6.06M shares | New | Oct 17, 2025 | SEC |
| Oct 24, 20254:13 PM ET | Ra Capital Management, L.P.and 3 others | 13G | 9.90%9.44M shares | +9.90 ppfrom 0.00% | Oct 17, 2025 | SEC |
| Oct 20, 20255:58 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 9.90%22.6M shares | New | Oct 17, 2025 | SEC |
| Aug 7, 202512:50 PM ET | Morgan Stanley | 13G/A | 6.70%4.75M shares | +1.30 ppfrom 5.40% | Jun 30, 2025 | SEC |
| Jul 16, 20257:02 PM ET | BlackRock, Inc. | 13G/A | 2.50%1.76M shares | –Below 5% | Jun 30, 2025 | SEC |
| May 15, 20258:09 PM ET | OrbiMed Advisors LLCand 1 other | 13G/A | 6.60%4.66M shares | – | Mar 31, 2025 | SEC |
| May 15, 20254:52 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 0.00%0 shares | –Below 5% | Mar 31, 2025 | SEC |
| May 7, 20251:39 PM ET | Wasatch Advisors Inc | 13G/A | 10.50%7.47M shares | – | Apr 30, 2025 | SEC |
| Feb 3, 20251:59 PM ET | Morgan Stanley | 13G | 5.40%3.83M shares | New | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell C4 Therapeutics, Inc. shares.
No Form 144 notices for C4 Therapeutics, Inc. are on file.